Bortezomib in systemic Light-Chain amyloidosis

Morie Gertz, Raymond Comenzo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The treatment for immunoglobin light-chain amyloidosis has included high-dose chemotherapy with stem cell transplantation. This effective technique is only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced respectable response rates, but tolerance of patients with amyloidosis to IMID's is less than in patients with multiple myeloma. The introduction of bortezomib for the management of light-chain amyloidosis is reviewed in this chapter. Bortezomib is highly active both as a single agent and in combination with corticosteroids in the treatment of immunoglobulin light-chain amyloidosis, with high hematologic and organ response rates reported. The agent can be used with renal insufficiency, including dialysis dependence. The agent has not been extensively tested in patients with class 3-4 heart failure.

Original languageEnglish (US)
Title of host publicationDrugs for HER-2-positive Breast Cancer
EditorsMichael Parnham, Jacques Bruinvels
Pages135-148
Number of pages14
DOIs
StatePublished - Dec 1 2010

Publication series

NameMilestones in Drug Therapy

Fingerprint

Amyloidosis
Light
Dexamethasone
Immunoglobulin Light Chains
Drug Therapy
Melphalan
Thalidomide
Stem Cell Transplantation
Multiple Myeloma
Renal Insufficiency
Dialysis
Adrenal Cortex Hormones
Therapeutics
Heart Failure
Bortezomib

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Gertz, M., & Comenzo, R. (2010). Bortezomib in systemic Light-Chain amyloidosis. In M. Parnham, & J. Bruinvels (Eds.), Drugs for HER-2-positive Breast Cancer (pp. 135-148). (Milestones in Drug Therapy). https://doi.org/10.1007/978-3-7643-8948-2_10

Bortezomib in systemic Light-Chain amyloidosis. / Gertz, Morie; Comenzo, Raymond.

Drugs for HER-2-positive Breast Cancer. ed. / Michael Parnham; Jacques Bruinvels. 2010. p. 135-148 (Milestones in Drug Therapy).

Research output: Chapter in Book/Report/Conference proceedingChapter

Gertz, M & Comenzo, R 2010, Bortezomib in systemic Light-Chain amyloidosis. in M Parnham & J Bruinvels (eds), Drugs for HER-2-positive Breast Cancer. Milestones in Drug Therapy, pp. 135-148. https://doi.org/10.1007/978-3-7643-8948-2_10
Gertz M, Comenzo R. Bortezomib in systemic Light-Chain amyloidosis. In Parnham M, Bruinvels J, editors, Drugs for HER-2-positive Breast Cancer. 2010. p. 135-148. (Milestones in Drug Therapy). https://doi.org/10.1007/978-3-7643-8948-2_10
Gertz, Morie ; Comenzo, Raymond. / Bortezomib in systemic Light-Chain amyloidosis. Drugs for HER-2-positive Breast Cancer. editor / Michael Parnham ; Jacques Bruinvels. 2010. pp. 135-148 (Milestones in Drug Therapy).
@inbook{8f8f1a4ebd1e44c7964ad5bfa925e235,
title = "Bortezomib in systemic Light-Chain amyloidosis",
abstract = "The treatment for immunoglobin light-chain amyloidosis has included high-dose chemotherapy with stem cell transplantation. This effective technique is only applicable to approximately 20{\%} of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50{\%}. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced respectable response rates, but tolerance of patients with amyloidosis to IMID's is less than in patients with multiple myeloma. The introduction of bortezomib for the management of light-chain amyloidosis is reviewed in this chapter. Bortezomib is highly active both as a single agent and in combination with corticosteroids in the treatment of immunoglobulin light-chain amyloidosis, with high hematologic and organ response rates reported. The agent can be used with renal insufficiency, including dialysis dependence. The agent has not been extensively tested in patients with class 3-4 heart failure.",
author = "Morie Gertz and Raymond Comenzo",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/978-3-7643-8948-2_10",
language = "English (US)",
isbn = "9783034600934",
series = "Milestones in Drug Therapy",
pages = "135--148",
editor = "Michael Parnham and Jacques Bruinvels",
booktitle = "Drugs for HER-2-positive Breast Cancer",

}

TY - CHAP

T1 - Bortezomib in systemic Light-Chain amyloidosis

AU - Gertz, Morie

AU - Comenzo, Raymond

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The treatment for immunoglobin light-chain amyloidosis has included high-dose chemotherapy with stem cell transplantation. This effective technique is only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced respectable response rates, but tolerance of patients with amyloidosis to IMID's is less than in patients with multiple myeloma. The introduction of bortezomib for the management of light-chain amyloidosis is reviewed in this chapter. Bortezomib is highly active both as a single agent and in combination with corticosteroids in the treatment of immunoglobulin light-chain amyloidosis, with high hematologic and organ response rates reported. The agent can be used with renal insufficiency, including dialysis dependence. The agent has not been extensively tested in patients with class 3-4 heart failure.

AB - The treatment for immunoglobin light-chain amyloidosis has included high-dose chemotherapy with stem cell transplantation. This effective technique is only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced respectable response rates, but tolerance of patients with amyloidosis to IMID's is less than in patients with multiple myeloma. The introduction of bortezomib for the management of light-chain amyloidosis is reviewed in this chapter. Bortezomib is highly active both as a single agent and in combination with corticosteroids in the treatment of immunoglobulin light-chain amyloidosis, with high hematologic and organ response rates reported. The agent can be used with renal insufficiency, including dialysis dependence. The agent has not been extensively tested in patients with class 3-4 heart failure.

UR - http://www.scopus.com/inward/record.url?scp=79953646973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953646973&partnerID=8YFLogxK

U2 - 10.1007/978-3-7643-8948-2_10

DO - 10.1007/978-3-7643-8948-2_10

M3 - Chapter

AN - SCOPUS:79953646973

SN - 9783034600934

T3 - Milestones in Drug Therapy

SP - 135

EP - 148

BT - Drugs for HER-2-positive Breast Cancer

A2 - Parnham, Michael

A2 - Bruinvels, Jacques

ER -